Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0.00978892627714877
Stock impact report

Dr. Reddy's Lab and Promius Pharma files NDA for its migraine candidate [Seeking Alpha]

Dr. Reddy's Laboratories Ltd (RDY) 
US:NYSE Investor Relations: drreddys.com/investors
Company Research Source: Seeking Alpha
Dr. Reddy's Lab and Promius Pharma files NDA for its migraine candidateDr. Reddy’s Laboratories (NYSE:RDY) and its subsidiary, Promius Pharma, LLCfiles New Drug Application (NDA) for its migraine candidate DFN-02 with the FDA.DFN-02 can effectively treat pain and associated symptoms during a migraine attack, including nausea, photophobia, and phonophobia. Upon approval, the product will be commercialized by Promius Pharma.DFN-02 is a novel investigational intranasal formulation in development for the acute treatment of migraine with or without aura.Click to subscribe to real-time analytics on RDYNow read:Abeona Therapeutics: Data Update - Part 2 » Show less Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
RDY alerts

from News Quantified
Opt-in for
RDY alerts

from News Quantified